- Home
- AUNA vs URGN Comparison
AUNA vs URGN Comparison
Compare AUNA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUNA
- URGN
- Stock Information
- Founded
- AUNA 1989
- URGN 2004
- Country
- AUNA Luxembourg
- URGN United States
- Employees
- AUNA N/A
- URGN N/A
- Industry
- AUNA
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- AUNA
- URGN Health Care
- Exchange
- AUNA NYSE
- URGN Nasdaq
- Market Cap
- AUNA 540.3M
- URGN 465.9M
- IPO Year
- AUNA 2024
- URGN 2017
- Fundamental
- Price
- AUNA $7.11
- URGN $10.63
- Analyst Decision
- AUNA Strong Buy
- URGN Strong Buy
- Analyst Count
- AUNA 4
- URGN 6
- Target Price
- AUNA $13.53
- URGN $40.75
- AVG Volume (30 Days)
- AUNA 27.9K
- URGN 419.1K
- Earning Date
- AUNA 05-25-2025
- URGN 03-10-2025
- Dividend Yield
- AUNA N/A
- URGN N/A
- EPS Growth
- AUNA N/A
- URGN N/A
- EPS
- AUNA 0.43
- URGN N/A
- Revenue
- AUNA $1,162,931,380.00
- URGN $90,398,000.00
- Revenue This Year
- AUNA $5.08
- URGN $43.60
- Revenue Next Year
- AUNA $6.75
- URGN $103.77
- P/E Ratio
- AUNA $16.30
- URGN N/A
- Revenue Growth
- AUNA 13.16
- URGN 9.29
- 52 Week Low
- AUNA $6.17
- URGN $9.03
- 52 Week High
- AUNA $10.56
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- AUNA N/A
- URGN 44.41
- Support Level
- AUNA N/A
- URGN $11.12
- Resistance Level
- AUNA N/A
- URGN $11.91
- Average True Range (ATR)
- AUNA 0.00
- URGN 0.56
- MACD
- AUNA 0.00
- URGN -0.07
- Stochastic Oscillator
- AUNA 0.00
- URGN 3.87
About AUNA AUNA S A
Auna SA is a healthcare provider. It operates hospitals and clinics in Mexico, Peru, and Colombia, and provides prepaid healthcare plans in Peru, and dental and vision plans in Mexico. Its network includes several healthcare network facilities, consisting of hospitals, outpatient, prevention, and wellness facilities. The company operates in the following segments; Oncosalud Peru, Healthcare services in Peru, Healthcare services in Colombia, and Healthcare services in Mexico. Key revenue is generated from Peru.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.